PolyTherics and MacroGenics Extend ADC Collaboration - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PolyTherics and MacroGenics Extend ADC Collaboration


PolyTherics, a technology solutions provider for biopharmaceutical development, has extended its antibody-drug conjugate (ADC) collaboration with US biotech company, MacroGenics. The extension follows the successful outcome of a research program undertaken in 2013 under a Research Collaboration and Option Agreement.

PolyTherics has developed ThioBridge for site-specific conjugation of cytotoxic payloads to antibodies to provide more stable and less heterogeneous ADCs. MacroGenics has two antibody technology platforms—a dual-affinity re-targeting (DART) bi-specific platform, in which a single recombinant molecule is able to target two different antigens, and Fc-optimized antibodies with improved effector function.

ThioBridge was used to conjugate a cytotoxic payload to a range of DART antibodies. MacroGenics and PolyTherics will collaborate in the application of its ThioBridge technology to a number of product candidates derived from MacroGenics’ antibody platforms.

MacroGenics has an option to licence the ThioBridge technology for the development of these product candidates and PolyTherics would receive development milestones and a single-digit percentage royalty on sales of any ThioBridge ADC derived from this collaboration.

Source: PolyTherics

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics

Click here